Tag:
flu
Latest Headlines
Latest Headlines
Inovio makes steps towards a universal flu vax
Inovio Pharmaceuticals thinks it is a step closer to the prize with a universal avian flu vax that has triggered protective responses against 6 h5N1 virus in one go in a Phase I clinical trial.
Swine flu vax could offer universal flu protection
Researchers in Canada are touting a 2009 swine flu shot as a potential route to a universal vaccine that could target all forms of influenza, according to data published in Frontiers of Immunology .
iBio shares jump with flu shot clinical trial
iBio's shares have jumped 21% with the announcement that it has completed the first Phase I clinical trial of its plant-based vaccine for H1N1 influenza.
Flu, over time, could increase Alzheimer's vulnerability
The flu and herpes viruses are bad enough already. But Harvard Medical School scientists believe that they may cause lasting brain cell damage, making sufferers vulnerable to neurodegenerative...
VC-backed biotech Alios lands flu drug deal with Univ. of Hong Kong
Alios BioPharma has taken its attack on infectious bugs to China, where the South San Francisco-based biotech has struck a deal with the University of Hong Kong's tech transfer outfit Versitech,
Investigators tout trial successes for hep C, influenza drugs at ICAAC
While Sangamo was making waves with its news on Carl June's latest gene therapy study, two other developers were reporting successes with their experimental treatments at ICAAC. Bristol-Myers Squibb (
Facebook app shows how people swap germs
Good friends share things: experiences, advice and--like it or not--germs. "PiggyDemic," a new Facebook app, lets people spread virtual bugs to their friends on the social network, allowing
BARDA grants Australia's Biota $231M flu vaccine contract
Just a month after granting major contracts to VaxInnate and Novavax , BARDA is giving $231 million to Australia-based Biota for the company's flu treatment laninamivir. The drug is a long acting
BioCryst hypes international pacts for peramivir
BioCryst Pharmaceuticals came out of the gate this morning touting new distribution deals for its closely-watched antiviral peramivir, but some analysts were doubtful that the developer had much new
Biota flags positive Phase III flu drug data
Australia's Biota says a late-stage Asian trial of a new influenza therapy aimed at the blockbuster space occupied by Tamiflu delivered positive data, setting it up to begin commercialization as it
